FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · Real-Time Price · USD
1.810
+0.050 (2.84%)
At close: Sep 4, 2026, 4:00 PM EDT
1.800
-0.010 (-0.55%)
After-hours: Sep 4, 2026, 6:29 PM EDT
FibroBiologics Employees
FibroBiologics had 15 employees as of December 31, 2025. The number of employees increased by 2 or 15.38% compared to the previous year.
Employees
15
Change (1Y)
2
Growth (1Y)
15.38%
Revenue / Employee
n/a
Profits / Employee
-$1,209,267
Market Cap
12.05M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 15 | 2 | 15.38% |
| Dec 31, 2024 | 13 | 3 | 30.00% |
| Dec 31, 2023 | 10 | 3 | 42.86% |
| Sep 30, 2023 | 8 | 1 | 14.29% |
| Jun 30, 2023 | 7 | - | - |
| Dec 31, 2022 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 41 |
| Senti Biosciences Holdings | 39 |
| Daré Bioscience | 24 |
| BioLineRx | 24 |
| IN8bio | 18 |
| Theriva Biologics | 16 |
| Kiora Pharmaceuticals | 13 |
| Azitra | 13 |
FBLG News
- 1 day ago - FibroBiologics announces USPTO issued patent on use of fibroblasts - TheFly
- 1 day ago - FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing - PRNewsWire
- 3 days ago - FibroBiologics announces USPTO issued patent for Fibroblast Conditioned Media - TheFly
- 3 days ago - FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media - PRNewsWire
- 8 days ago - FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - PRNewsWire
- 9 days ago - FibroBiologics Regains Compliance with Nasdaq Trading Rules - PRNewsWire
- 11 days ago - FibroBiologics Appoints Leigh Steinberg to Board of Directors - PRNewsWire
- 15 days ago - FibroBiologics says Australian patent accepted for Cannabidiol Adjuvant Therapy - TheFly